Metformin Mediates Protection against Legionella Pneumonia through Activation of AMPK and Mitochondrial Reactive Oxygen Species

Chiaki Kajiwara, Yu Kusaka, Soichiro Kimura, Tetsuo Yamaguchi, Yuta Nanjo, Yoshikazu Ishii, Heiichiro Udono, Theodore J. Standiford, Kazuhiro Tateda

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In Legionella pneumophila infection, macrophages play a critical role in the host defense response. Metformin, an oral drug for type 2 diabetes, is attracting attention as a new supportive therapy against a variety of diseases, such as cancer and infectious diseases. The novel mechanisms for metformin actions include modulation of the effector functions of macrophages and other host immune cells. In this study, we have examined the effects of metformin on L. pneumophila infection in vitro and in vivo. Metformin treatment suppressed growth of L. pneumophila in a time- and concentration-dependent fashion in bone marrow-derived mac-rophages, RAW cells (mouse), and U937 cells (human). Metformin induced phosphorylation of AMP-activated protein kinase (AMPK) in L. pneumophila-infected bone marrow-derived macrophages, and the AMPK inhibitor Compound C negated metformin-mediated growth suppression. Also, metformin induced mitochondrial reactive oxygen species but not phagosomal NADPH oxidase-derived reactive oxygen species. Metformin-mediated growth suppression was mitigated in the presence of the reactive oxygen species scavenger glutathione. In a murine L. pneumophila pneumonia model, metformin treatment improved survival of mice, which was associated with a significant reduction in bacterial number in the lung. Similar to in vitro observations, induction of AMPK phosphorylation and mitochondrial ROS was demonstrated in the infected lungs of mice treated with metformin. Finally, glutathione treatment abolished metformin effects on lung bacterial clearance. Collectively, these data suggest that metformin promotes mitochondrial ROS production and AMPK signaling and enhances the bactericidal activity of macro-phages, which may contribute to improved survival in L. pneumophila pneumonia.

Original languageEnglish
Pages (from-to)623-631
Number of pages9
JournalJournal of Immunology
Volume200
Issue number2
DOIs
Publication statusPublished - Jan 15 2018

Fingerprint

Legionella
AMP-Activated Protein Kinases
Metformin
Reactive Oxygen Species
Pneumonia
Legionella pneumophila
Legionnaires' Disease
Macrophages
Lung
Glutathione
Growth
Phosphorylation
U937 Cells
NADPH Oxidase
Protein Kinase Inhibitors
Bacteriophages
Type 2 Diabetes Mellitus
Communicable Diseases

ASJC Scopus subject areas

  • Immunology

Cite this

Metformin Mediates Protection against Legionella Pneumonia through Activation of AMPK and Mitochondrial Reactive Oxygen Species. / Kajiwara, Chiaki; Kusaka, Yu; Kimura, Soichiro; Yamaguchi, Tetsuo; Nanjo, Yuta; Ishii, Yoshikazu; Udono, Heiichiro; Standiford, Theodore J.; Tateda, Kazuhiro.

In: Journal of Immunology, Vol. 200, No. 2, 15.01.2018, p. 623-631.

Research output: Contribution to journalArticle

Kajiwara, C, Kusaka, Y, Kimura, S, Yamaguchi, T, Nanjo, Y, Ishii, Y, Udono, H, Standiford, TJ & Tateda, K 2018, 'Metformin Mediates Protection against Legionella Pneumonia through Activation of AMPK and Mitochondrial Reactive Oxygen Species', Journal of Immunology, vol. 200, no. 2, pp. 623-631. https://doi.org/10.4049/jimmunol.1700474
Kajiwara, Chiaki ; Kusaka, Yu ; Kimura, Soichiro ; Yamaguchi, Tetsuo ; Nanjo, Yuta ; Ishii, Yoshikazu ; Udono, Heiichiro ; Standiford, Theodore J. ; Tateda, Kazuhiro. / Metformin Mediates Protection against Legionella Pneumonia through Activation of AMPK and Mitochondrial Reactive Oxygen Species. In: Journal of Immunology. 2018 ; Vol. 200, No. 2. pp. 623-631.
@article{14248319df2840e68f32e764b426e7b0,
title = "Metformin Mediates Protection against Legionella Pneumonia through Activation of AMPK and Mitochondrial Reactive Oxygen Species",
abstract = "In Legionella pneumophila infection, macrophages play a critical role in the host defense response. Metformin, an oral drug for type 2 diabetes, is attracting attention as a new supportive therapy against a variety of diseases, such as cancer and infectious diseases. The novel mechanisms for metformin actions include modulation of the effector functions of macrophages and other host immune cells. In this study, we have examined the effects of metformin on L. pneumophila infection in vitro and in vivo. Metformin treatment suppressed growth of L. pneumophila in a time- and concentration-dependent fashion in bone marrow-derived mac-rophages, RAW cells (mouse), and U937 cells (human). Metformin induced phosphorylation of AMP-activated protein kinase (AMPK) in L. pneumophila-infected bone marrow-derived macrophages, and the AMPK inhibitor Compound C negated metformin-mediated growth suppression. Also, metformin induced mitochondrial reactive oxygen species but not phagosomal NADPH oxidase-derived reactive oxygen species. Metformin-mediated growth suppression was mitigated in the presence of the reactive oxygen species scavenger glutathione. In a murine L. pneumophila pneumonia model, metformin treatment improved survival of mice, which was associated with a significant reduction in bacterial number in the lung. Similar to in vitro observations, induction of AMPK phosphorylation and mitochondrial ROS was demonstrated in the infected lungs of mice treated with metformin. Finally, glutathione treatment abolished metformin effects on lung bacterial clearance. Collectively, these data suggest that metformin promotes mitochondrial ROS production and AMPK signaling and enhances the bactericidal activity of macro-phages, which may contribute to improved survival in L. pneumophila pneumonia.",
author = "Chiaki Kajiwara and Yu Kusaka and Soichiro Kimura and Tetsuo Yamaguchi and Yuta Nanjo and Yoshikazu Ishii and Heiichiro Udono and Standiford, {Theodore J.} and Kazuhiro Tateda",
year = "2018",
month = "1",
day = "15",
doi = "10.4049/jimmunol.1700474",
language = "English",
volume = "200",
pages = "623--631",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "2",

}

TY - JOUR

T1 - Metformin Mediates Protection against Legionella Pneumonia through Activation of AMPK and Mitochondrial Reactive Oxygen Species

AU - Kajiwara, Chiaki

AU - Kusaka, Yu

AU - Kimura, Soichiro

AU - Yamaguchi, Tetsuo

AU - Nanjo, Yuta

AU - Ishii, Yoshikazu

AU - Udono, Heiichiro

AU - Standiford, Theodore J.

AU - Tateda, Kazuhiro

PY - 2018/1/15

Y1 - 2018/1/15

N2 - In Legionella pneumophila infection, macrophages play a critical role in the host defense response. Metformin, an oral drug for type 2 diabetes, is attracting attention as a new supportive therapy against a variety of diseases, such as cancer and infectious diseases. The novel mechanisms for metformin actions include modulation of the effector functions of macrophages and other host immune cells. In this study, we have examined the effects of metformin on L. pneumophila infection in vitro and in vivo. Metformin treatment suppressed growth of L. pneumophila in a time- and concentration-dependent fashion in bone marrow-derived mac-rophages, RAW cells (mouse), and U937 cells (human). Metformin induced phosphorylation of AMP-activated protein kinase (AMPK) in L. pneumophila-infected bone marrow-derived macrophages, and the AMPK inhibitor Compound C negated metformin-mediated growth suppression. Also, metformin induced mitochondrial reactive oxygen species but not phagosomal NADPH oxidase-derived reactive oxygen species. Metformin-mediated growth suppression was mitigated in the presence of the reactive oxygen species scavenger glutathione. In a murine L. pneumophila pneumonia model, metformin treatment improved survival of mice, which was associated with a significant reduction in bacterial number in the lung. Similar to in vitro observations, induction of AMPK phosphorylation and mitochondrial ROS was demonstrated in the infected lungs of mice treated with metformin. Finally, glutathione treatment abolished metformin effects on lung bacterial clearance. Collectively, these data suggest that metformin promotes mitochondrial ROS production and AMPK signaling and enhances the bactericidal activity of macro-phages, which may contribute to improved survival in L. pneumophila pneumonia.

AB - In Legionella pneumophila infection, macrophages play a critical role in the host defense response. Metformin, an oral drug for type 2 diabetes, is attracting attention as a new supportive therapy against a variety of diseases, such as cancer and infectious diseases. The novel mechanisms for metformin actions include modulation of the effector functions of macrophages and other host immune cells. In this study, we have examined the effects of metformin on L. pneumophila infection in vitro and in vivo. Metformin treatment suppressed growth of L. pneumophila in a time- and concentration-dependent fashion in bone marrow-derived mac-rophages, RAW cells (mouse), and U937 cells (human). Metformin induced phosphorylation of AMP-activated protein kinase (AMPK) in L. pneumophila-infected bone marrow-derived macrophages, and the AMPK inhibitor Compound C negated metformin-mediated growth suppression. Also, metformin induced mitochondrial reactive oxygen species but not phagosomal NADPH oxidase-derived reactive oxygen species. Metformin-mediated growth suppression was mitigated in the presence of the reactive oxygen species scavenger glutathione. In a murine L. pneumophila pneumonia model, metformin treatment improved survival of mice, which was associated with a significant reduction in bacterial number in the lung. Similar to in vitro observations, induction of AMPK phosphorylation and mitochondrial ROS was demonstrated in the infected lungs of mice treated with metformin. Finally, glutathione treatment abolished metformin effects on lung bacterial clearance. Collectively, these data suggest that metformin promotes mitochondrial ROS production and AMPK signaling and enhances the bactericidal activity of macro-phages, which may contribute to improved survival in L. pneumophila pneumonia.

UR - http://www.scopus.com/inward/record.url?scp=85044752379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044752379&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1700474

DO - 10.4049/jimmunol.1700474

M3 - Article

VL - 200

SP - 623

EP - 631

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 2

ER -